Defunct Company
Total Trials
11
As Lead Sponsor
As Collaborator
0
Total Enrollment
456
NCT01147406
Safety and Tolerability Study of N6022 in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 31, 2010
Completion: Jun 30, 2011
NCT01316315
Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma
Phase: Phase 1/2
Start: Mar 31, 2011
Completion: Dec 31, 2011
NCT01339897
A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects
Start: Apr 30, 2011
Completion: Aug 31, 2011
NCT01746784
Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
Start: Feb 28, 2014
Completion: May 31, 2014
NCT02013388
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects
Completion: Feb 28, 2015
NCT02227888
PK Study of N91115 in Cystic Fibrosis Patients
Start: Oct 31, 2014
Completion: Jan 31, 2015
NCT02275936
Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation
Start: Feb 28, 2015
Completion: Jul 31, 2015
NCT02500667
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
Start: Jun 30, 2015
Completion: Aug 31, 2015
NCT02589236
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
Phase: Phase 2
Start: Nov 30, 2015
Completion: Dec 31, 2016
NCT02724527
Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor
Start: Apr 30, 2016
Completion: Apr 30, 2017
NCT02934139
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)
Start: Oct 31, 2016
Completion: Jan 31, 2017